Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, was featured in a MedTech Intelligence video Q&A, titled “Progress of FDA’s Office of Combination Products.”
Following is an excerpt:
Bradley Merrill Thompson, partner at Epstein Becker Green, discusses the Office of Combination Products and its development over the past decade, as well as the challenges it faces in the area of policy making, at this year’s MedTech IntelligenceCombination Products Conference in Washington, DC. He shares his thoughts on the alignment between OCP and CDRH, CDER, and CBER as well as the role of human factors in combination products.